Objective:To evaluate the effect of milrinone in treating refractory heart failure.Methods:5mg of milrinone in 250ml of 5% Glucose or 0.9% NaCl Solution were given daily by intravenous drip to 56 cases of refractory heart failure for a period of consecutive 7 days.The symptoms and signs were observed before and after the treatment,heart rate,blood pressure and heart function examined by Doppler echocardiography.Results:a.The total effective rate was 85.7%.b.The left ventricular ejection fraction (LVEF) and fraction shortening (FS) were increased significantly (P＜0.01) after treatment.The rate of filling velocity in early diastole (E) over that in late diastole (A) was increased significantly (P＜0.05).Conclusion:Milrinone has good effect for treating refractory heart failure.It improves not only the cardiac systolic function but also the diastolic function.

PURPOSE: Results on the clinical utility of cell therapy for ST-elevated myocardial infarction (STEMI) are controversial. This study sought to analyze the efficacy of treatment with intracoronary bone marrow mononuclear cells (BMMC) on left ventricular (LV) function and remodeling and LV diastolic and systolic function in patients with STEMI. MATERIALS AND METHODS: Literature search of PubMed and EMBASE databases between 2004 and 2017 was performed for randomized controlled trials in STEMI patients who underwent successful percutaneous coronary intervention and received intracoronary BMMC therapy. The defined end points were left ventricular ejection fraction (LVEF), left ventricular end-diastolic volume (LVEDV), and left ventricular end-systolic volume (LVESV). Also, sensitivity analysis and several subgroup analyses based on follow-up duration, timing of injection, doses of cells, and imaging modalities were conducted to strengthen the statistic power of the study. RESULTS: A total of 22 trials with 1360 patients were available for the current meta-analysis. The pooled statistics showed a significant improvement in LVEF {2.58 [95% confidence interval (CI), 1.32, 3.84]; p < 0.001}, LVEDV [−3.73, (95% CI, −6.94, −0.52), p=0.02], and LVESV [−4.67, (95% CI, −7.07, −2.28), p < 0.001] in the BMMC group, compared with the control group. However, in sensitivity analysis, a significant reduction in LVEDV disappeared, while the outcomes of LVEF and LVESV remained unchanged. The same results were presented in the subgroup analysis adjusting for imaging modalities and timing of cells injection. CONCLUSION: BMMC transplantation in patients with STEMI was found to lead to improvement in LVEF, LVEDV, and LVESV parameters, indicating that cell therapy has a potential beneficial effect on LV remodeling and function.
Bone Marrow Transplantation ; Bone Marrow* ; Cell- and Tissue-Based Therapy ; Follow-Up Studies ; Humans ; Myocardial Infarction* ; Percutaneous Coronary Intervention ; Stroke Volume ; Ventricular Dysfunction, Left